NIH awards Trevena $460,000 to Develop Drug for Major Depressive Disorder

Trevena, Inc. has been awarded a five-year cooperative agreement from the National Institutes of Health to develop a novel biased ligand to the delta opioid receptor for treating major depressive disorder. The award, made through the NIH Blueprint Neurotherapeutics Network, will fund activities at Trevena and leverage resources at the 15 agency institutes and centers in the network over a five-year period to work toward Phase 1 clinical development of the drug. The award includes $460,000 in direct funding and access to millions of dollars worth of contracted research services.

Source:

Trevena Receives Major New Award from NIH To Develop Delta Opioid Biased Ligand Drug [Press Release]